Skip to Content

Join the 'Antihemophilic Factor' group to help and get support from people like you.

Antihemophilic Factor News

Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings

Posted 29 Dec 2016 by Drugs.com

Lexington, Mass. – December 27, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved Adynovate [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, in pediatric patients under 12 years of age. The FDA also approved Adynovate for use in sur ...

FDA Approves Afstyla (Antihemophilic Factor (Recombinant), Single Chain) for Hemophilia A

Posted 8 Jun 2016 by Drugs.com

KING OF PRUSSIA, Pa. — 26 May 2016 – CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved Afstyla [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A. Afstyla is the first and only single-chain product for hemophilia A that is specifically designed f ...

FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A

Posted 18 Mar 2016 by Drugs.com

WHIPPANY, N.J., March 17, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, ...

FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A

Posted 16 Nov 2015 by Drugs.com

November 13, 2015 – The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. ...

FDA Approves Nuwiq (Antihemophilic Factor [Recombinant]) for Hemophilia A

Posted 17 Sep 2015 by Drugs.com

HOBOKEN, N.J. September 15th, 2015: Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved Nuwiq, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The Nuwiq approval includes on-demand treatment and control of bleeding episodes; routine prophylaxis to reduce the frequency of bleeding episodes; and ...

Kids' Hemophilia Drugs a Big Part of State Medicaid Spending

Posted 31 Jul 2015 by Drugs.com

FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in ...

FDA Approves Obizur [Antihemophilic Factor (Recombinant)] for Acquired Hemophilia A

Posted 27 Oct 2014 by Drugs.com

DEERFIELD, Ill., October 24, 2014 - Baxter International Inc. today announced that the United States Food and Drug Administration (FDA) has approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (AHA), a very rare and potentially life-threatening acute bleeding disorder. Obizur was granted orphan-drug ...

FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

Posted 9 Jun 2014 by Drugs.com

June 6, 2014 – The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. Eloctate is approved to help control and prevent bleeding ...

New Hemophilia Remedy Eloctate Offers Potential for Fewer Injections

Posted 9 Jun 2014 by Drugs.com

MONDAY, June 9, 2014 – Eloctate, Antihemophilic Factor Fc Fusion has been approved by the U.S. Food and Drug Administration for people with Hemophilia A. It's designed to require less frequent injections than standard therapies used to reduce the frequency of bleeding episodes in people with the disorder, the FDA said in a news release. Hemophilia A is an inherited bleeding disorder that affects ...

NovoEight (turoctocog alfa) Receives Approval from the FDA

Posted 21 Oct 2013 by Drugs.com

Bagsværd, Denmark, 16 October 2013 – Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application (BLA) for recombinant coagulation factor VIII, Novoeight. The FDA approved Novoeight for use in adults and children with hemophilia A for: Control and prevention of bleeding Perioperative management Routine prophylaxis to prevent or re ...

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia A

Related Drug Support Groups

Advate, Adynovate, Recombinate, Bioclate, Biostate, Afstyla, ReFacto, Monarc-M, Liberate, view more... Monoclate, Monoclate-P, Hyate:C, Replenate, Genarc, Advate rAHF-PFM, Kovaltry, Nuwiq, Koate-DVI, Koate-HP, Kogenate, Kogenate Bayer, NovoEight, Kogenate FS, Kogenate FS with Bioset, Beriate P, Helixate, Helixate FS, Helixate NexGen, Factane, Fanhdi, Eloctate, Hemofil-M, Obizur, Xyntha

Antihemophilic Factor Patient Information at Drugs.com